Prostate And Other Male Cancers
The 8-year rates of OS were 76 and 75% with 79.2 and 70.2 Gy, respectively (hazard ratio, 1.00; 95% confidence interval, 0.83 to 1.20; P=0.98). The 8-year cumulative rates of distant metastases were 4 and 6% for the 79.2- and 70.2-Gy arms, respectively (hazard ratio, 0.65; 95% confidence interval, 0.42 to 1.01; P=0.05).
Erleada is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer.
The researchers found that the median metastasis-free survival was 40.5 months in the apalutamide group and 16.2 months in the placebo group in the planned primary analysis performed after 378 events had occurred. Also significantly longer time to symptomatic progression was seen with apalutamide versus placebo.
The FDA approval was supported by results from the Phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled LATITUDE trial (N=1,199) which evaluated Zytiga 1000mg once daily in combination with prednisone 5mg once daily vs placebo in newly diagnosed, metastatic high-risk CSPC patients who had not received prior cytotoxic chemotherapy.
The researchers found that there were more obese patients in the high- versus low-/intermediate-risk group (41.2 versus 32.0%; P=0.006).
The researchers found that high adherence to a Mediterranean dietary pattern, rich in fruits and vegetables, fish, legumes, and olive oil, correlated with a lower risk of prostate cancer with a Gleason score greater than 6.
"Polygenic hazard scores can be used for personalized genetic risk estimates that can predict for age at onset of aggressive PCa," the authors write.
Within 4 months of enzalutamide initiation, four patients (1.1%) had at least one confirmed seizure; three additional patients (0.8%) experienced a seizure within four months following the 4-month study period.
Apalutamide, an investigational, next generation oral androgen receptor inhibitor, was assessed for safety and efficacy in the Phase 3 pivotal trial, ARN-509-003 (SPARTAN), which the NDA is based on.
Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).
As home genetic testing grows, patients will be bringing their results to physicians for reaction and response. Physicians will need to be proactively prepared.
Researchers of 2 newly published studies found that abiraterone (Zytiga) lowers risk of death by nearly 40% when added to standard androgen deprivation therapy.
In the per-protocol analysis, the researchers found that the average survival after surgery for those receiving capecitabine was 53 months, compared to 36 months for those who only had surgery. Existing Treatment Should be Considered Standard of Care in Biliary Cancer
For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.
The 2017 AUA list contains evidence-based recommendations to guide conversations between physicians and patients about what care is appropriate.
Nearly 7,000 Italian men participating in the Moli-sani epidemiological study aged ≥50 years were monitored for an average of 4.25 years.
The USPSTF performed a systematic review of the existing evidence and concluded that the potential benefits and harms of prostate-specific antigen (PSA)-based screening are "closely balanced" in men aged 55-69 years.
The researchers found that survival curves showed that metformin use with docetaxel did not significantly improve prostate cancer-specific survival.
These studies identified links to increased risks of thyroid, testicular and breast cancer, nonalcoholic fatty liver disease and even the early onset of puberty for boys, which can lead to diseases in adulthood.
Six hours of sleep a night was linked to a 29% higher risk of prostate cancer death compared to 7 hours. Men who were 65 or older showed no difference in the risk of death from prostate cancer.
The researchers found that regular aspirin use correlated with reduced risk of total mortality compared with nonregular use (multivariable-adjusted relative risks [RRs], 0.93 and 0.89 for women and men, respectively).
The detection rate of high-grade prostate cancer was comparable for 6-TRUS-Bx, 12-TRUS-Bx, and MRI ± TBx; 10, 12, and 11%, respectively.
Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.
The researchers found that the adjusted mean sexual domain score decreased more for radical prostatectomy than for EBRT at three years.